Fourth, as polymorphisms within TCF7L2 possibly impair the glucagon like peptide-1 induced insulin secretion [9], which in turn could lead to a lower postprandial insulin secretion, we might expect to see a stronger effect among patients with impaired glucose tolerance. This evidence concerns the gene INS and Impaired glucose tolerance.